Annotation of HCSC Label for metoclopramide and CYB5R1, CYB5R2, CYB5R3, CYB5R4, G6PD

Informative PGxLearn more about Label Annotation Levels of Evidence(opens in new window)

PharmGKB ID

PA166345821

Summary

The product monograph for metoclopramide notes that patients with NADH-cytochrome b5 reductase deficiency have an increased risk of developing methemglobinemia and/or sulfhemoglobinemia when treated with metoclopramide. The label also mentions G6PD; patients with G6PD deficiency experiencing metoclopramide-induced methemoglobinemia should not be given methylene blue.

Annotation

Excerpt from the metoclopramide (pms-METOCLOPRAMIDE TABLETS) product monograph:

Metoclopramide-treated patients with NADH-cytochrome b5 reductase deficiency are at an increased risk of developing methemoglobinemia and/or sulfhemoglobinemia. For patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency with metoclopramide-induced methemoglobinemia, methylene blue treatment is not recommended. Methylene blue may cause hemolytic anemia in patients with G6PD deficiency, which may be fatal.

For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the metoclopramide product monograph.

*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.

More information about drug label annotations on PharmGKB

Evidence for Clinical Annotations

This annotation has been used as evidence for the following clinical annotations.

    Source

    1. Drugs@HCSC: Drug Product pms-METOCLOPRAMIDE TABLETS (metoclopramide), PHARMASCIENCE INC.
      Has PGx

    History

    No history available.